Ranolazine versus placebo in patients with ischemic cardiomyopathy and persistent chest pain or dyspnea despite optimal medical and revascularization therapy: randomized, double-blind crossover pilot study

BACKGROUND: Patients with ischemic cardiomyopathy (ICM) may continue to experience persistent chest pain and/or dyspnea despite pharmacologic therapy and revascularization. We hypothesized that ranolazine would reduce anginal symptoms or dyspnea in optimally treated ICM patients. METHODS: In this ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Shammas, Nicolas W, Shammas, Gail A, Keyes, Kathleen, Duske, Shawna, Kelly, Ryan, Jerin, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376266/
https://www.ncbi.nlm.nih.gov/pubmed/25848292
http://dx.doi.org/10.2147/TCRM.S82288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376266/
https://www.ncbi.nlm.nih.gov/pubmed/25848292
http://dx.doi.org/10.2147/TCRM.S82288

Ejemplares similares